Timothy A. Springer, Director, 10% Owner at Cartesian Therapeutics, Inc. (RNAC), bought 18,400 shares at $0.61 ($11K) on 2024-03-18, disclosed to the SEC on 2024-03-28.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.69 | 800 | $552 | 4.8% |
| 2 | $0.65 | 800 | $520 | 4.6% |
| 3 | $0.66 | 2,400 | $2K | 13.9% |
| 4 | $0.66 | 4,800 | $3K | 27.8% |
| 5 | $0.65 | 1,200 | $780 | 6.8% |
| 6 | $0.61 | 1,200 |
| $732 |
| 6.4% |
| 7 | $0.58 | 3,200 | $2K | 16.3% |
| 8 | $0.53 | 2,000 | $1K | 9.3% |
| 9 | $0.56 | 1,200 | $672 | 5.9% |
| 10 | $0.61 | 800 | $488 | 4.3% |
| Total | $0.62 avg | 18,400 | $11K | 100% |
| Filing → |
| TECX | BUY | 2025-04-09 | $17.1M | — | Filing → |
| RNAC | BUY | 2025-03-20 | $2.7M | — | Filing → |
| TECX | BUY | 2025-02-07 | $47.0M | — | Filing → |